TheraPanacea
ART-Plan by TheraPanacea is a CE-marked and FDA-authorised AI suite for radiation oncology. It auto-contours 270+ organs at risk and lymph nodes, generates treatment plans and flags adaptive replanning, inside the clinic's existing workflow.
What is TheraPanacea?
TheraPanacea is a Paris-based medical AI company, a spin-off of Paris-Saclay University with a US office in Cambridge, Massachusetts. Its flagship product, ART-Plan (and the newer ART-Plan+), is presented as the AI companion to a radiotherapy department's treatment planning system, and it is a regulated medical device with its own UDI codes and published technical information sheets. The company timeline records the 2017 founding, CE and FDA approval in 2019 for commercial use in organ-at-risk delineation, expansion across five continents in 2021, and AI for planning and adaptive workflows in 2025.
The suite has three modules. Segmentation automatically delineates 270+ organs at risk and lymph nodes on CT, MR and synthetic CT, adds MRI tumour segmentation for glioblastoma and multiple metastases, brachytherapy structures, and multi-modality fusion with rigid and deformable registration across CT, MR, PET, CBCT and 4DCT. Eight structure libraries cover head and neck, thorax, breast, abdomen, male and female pelvis and brain, each aligned to published delineation guidelines such as DAHANCA 2020, EPTN, ESTRO and RTOG consensus papers. The vendor cites a peer-reviewed reduction of manual tasks of more than 93%. Planning, marketed as SmartPlan, builds vendor-agnostic treatment plans in minutes, optimises target coverage and organ sparing, reduces variability between planners and exports automatically to the treatment planning system. Adaptive, or AdaptBox, runs in the background: it generates synthetic CT from CBCT, re-delineates organs, propagates target contours, recalculates and compares dose, and raises protocol-driven alerts in a customisable dashboard.
The company reports 300 clinical sites, roughly a thousand years of clinical time saved, 75+ employees and 23 nationalities. Nothing about it is self-service: intended users are trained clinicians familiar with radiation therapy — medical physicists, dosimetrists and radiation oncologists — every contour must be verified by an authorised person, and the software is contraindicated outside radiotherapy and unsuitable as a basis for diagnosis.
What it does
- Automatically contour 270+ organs at risk and lymph nodes on CT, MR and synthetic CT in minutes
- Generate a complete radiotherapy treatment plan and export it automatically to the treatment planning system
- Recalculate and compare delivered versus planned dose on the day's imaging, then raise protocol-based replanning alerts
- Produce synthetic CT from MR or from CBCT for supported anatomies
- Fuse multi-modality images with rigid and deformable registration across CT, MR, PET, CBCT and 4DCT
- Delineate tumours on MRI, including glioblastoma and multiple metastases
- Feed a customisable dashboard and report templates for treatment monitoring
When to use TheraPanacea / When not to
A quick filter to help you decide if TheraPanacea is the right fit.
When to use TheraPanacea
- Radiation oncologists who spend hours delineating organs at risk before every treatment plan
- Medical physicists and dosimetrists looking to standardise planning quality and cut turnaround time
- Radiotherapy departments running offline adaptive workflows from daily CBCT imaging
- Cancer centres already equipped with Monaco-Mosaiq, Eclipse-ARIA or RayStation
- Clinical trial teams that need consistent, guideline-based contouring quality control across sites
When not to use TheraPanacea
- Anyone outside radiotherapy: the software is formally contraindicated beyond that context
- Clinicians looking for a diagnostic tool, which the vendor explicitly says this is not
- Patients and members of the public, since use is restricted to trained professionals in a clinical setting
- Solo practitioners or small teams wanting self-service sign-up, as there is no free plan, trial or public price
- Mobile-first users, because the platform is not usable on tablets or smartphones
How to use TheraPanacea
A typical end-to-end flow, from setup to results.
- Contact TheraPanacea through the Request a Demo form, choosing between a demo, a general enquiry or a partnership
- Agree a contract, then decide between an on-site server and the cloud option
- Specify the server environment before the installation date: an air-conditioned room and a high-voltage outlet are required
- Have TheraPanacea perform the installation, since self-installation is explicitly forbidden
- Install the ART-Plan Connect companion application on a local Windows machine if the workflow needs it
- Import DICOM studies (CT, MR, PET, 4DCT, CBCT), compressing them into a .zip file when loading from local storage
- Check the required DICOM tags, especially patient position and frame of reference, against the DICOM Conformance Statement
- Run automatic contouring, which takes roughly two to three minutes per anatomy depending on the number of structures
- Review, validate and if necessary correct the proposed contours with the manual and semi-automatic tools
- Generate the plan with SmartPlan, import it into the treatment planning system for dose calculation, review and approval, then monitor the course of treatment in the Adaptive dashboard
Pros & Cons
Pros
- A regulated medical device, CE marked and FDA authorised since 2019 for organ-at-risk delineation
- Time savings backed by published evidence: more than 93% fewer manual tasks, and a five- to sixfold faster delineation reported by Gustave Roussy
- Unusually broad anatomical coverage, with 270+ structures across eight libraries by region and modality
- Contours aligned to published international guidelines, which directly attacks inter-operator variability
- Vendor-agnostic planning and OIS/TPS interoperability rather than lock-in to one hardware ecosystem
- Real third-party integrations, including segmentation embedded in Brainlab Elements and a partnership with LAP's RadCalc
- A visible commitment that personal health data is not transferred outside the European Economic Area
Cons
- No public pricing at all: no tariff page, no plans, no free trial, everything routes through a demo request
- No published terms of service or licence agreement; the only legal page covers the website, not the product
- Model availability varies by market and no list of covered markets is ever published
- Automatic plan generation is validated on three configurations only: Monaco-Mosaiq, Eclipse-ARIA and RayStation
- AdaptBox synthetic CT is restricted to Elekta and Varian CBCT; other scanners may give incorrect results
- Heavy on-premise setup: a dedicated server, an air-conditioned room, a high-voltage outlet and firewall work
- No public API, no developer documentation, and no usable experience on tablets or smartphones
Pricing & Plans
TheraPanacea publishes no pricing information. There is no permanent free plan and no free trial announced anywhere on the site, and the complete sitemap contains no pricing page, so no entry-level price or currency can be quoted. ART-Plan is sold under contract to healthcare institutions: the only route to a quotation is the demo request form, after which terms — including whether the cloud option is included — are set contractually.
Data, GDPR & hosting
A consolidated view of how TheraPanacea handles your data.
GDPR overview
GDPR compliance is claimed in plain words: the privacy policy states that personal data and privacy are protected by TheraPanacea and handled in accordance with the General Data Protection Regulation. Four data subject rights are listed — access, erasure, rectification and objection — with dpo@therapanacea.eu as the contact address, repeated on the contact page, and a pointer to the French CNIL. Every page footer carries a stronger commitment: no transfers of personal health data outside the European Economic Area. As the publisher is established in Paris, no Article 27 representative is required. The gaps are real, though: the policy dates from 11 November 2023, addresses only website visitors, and nowhere covers a data processing agreement, a subprocessor list, retention periods or a minimum age.
Who owns the data?
TheraPanacea publishes no terms and conditions and no licence agreement, so ownership of clinical data is not addressed publicly and is instead governed by the commercial contract. The only legal page, Legal Info & Privacy Policy (last updated 11 November 2023), covers website visitors only, and names TheraPanacea as the controller for data collected through the site. In practice, imaging data stays with the customer: ART-Plan runs on a server installed at the clinical site or on a contractual cloud option, and DICOM export back to the treatment planning system is driven by the user. The vendor warns that deleting DICOM files from the platform is irreversible and that copies should be kept elsewhere.
Reuse rights
Because no terms of use are published, the site sets out no restriction on how a customer may reuse its own outputs. Functionally, reuse is designed in: contours, registered images, synthetic CT and generated plans are all exportable in DICOM to other software, and the Planning module advertises automatic export to the treatment planning system. Two caveats come from the vendor itself. Non-validated contours can technically be exported, but must be validated before being used for treatment planning. And generated images such as projections or pseudo-CT must be traceable through their DICOM tags so they are never mistaken for original acquisitions. On the website side, data collected through the demo request form and Google Analytics serves contact and audience measurement only.
Data retention & training
Hosting summary
The clearest statement is repeated in the footer of every page: no transfers of personal health data to countries outside the European Economic Area. Beyond that geographic boundary, no specific hosting country or provider is named for patient data. Two deployment modes exist: a server installed inside the clinical facility, or a cloud option agreed in the contract. In cloud mode, results are automatically sent out to the DICOM output applications the customer has configured, so the destination of exported data is under the customer's control. One point deserves care when reading the privacy policy: the only named host, one.com SARL in Paris, hosts the corporate website www.therapanacea.eu, not ART-Plan patient data. Similarly, therapanacea.com resolves to a US-located IP address, which reflects delivery of the marketing site rather than where clinical data lives. The publisher is established in France.
Things to keep in mind
Risks and trade-offs to weigh before adopting TheraPanacea.
- Automation bias is the central risk: accepting a proposed contour without truly reviewing it, because it looks plausible and the queue is long
- Skill erosion, as zero-click contouring can quietly hollow out the delineation expertise of junior staff who never learn the hard cases
- Output quality follows image quality: artefacts, implants, low resolution or lossy compression can produce wrong contours that still look clean
- Incorrect DICOM metadata, such as patient position or frame of reference, can cause studies to be grouped or registered wrongly
- Exporting non-validated contours to another system, which the vendor explicitly advises against, can propagate an unchecked structure into treatment
- Deletion inside the platform is irreversible, so a routine cleanup without an external copy is unrecoverable
- Contractual dependency: beyond the contract period the vendor no longer maintains the installed version, and patient-data terms live in that contract rather than in any public document
Setup & Integrations
Technical difficulty
High, and deliberately so. Customers cannot install ART-Plan themselves: TheraPanacea performs the installation, and the environment must be specified in advance. An on-premise deployment needs a dedicated server in an air-conditioned room with a high-voltage outlet, with no other devices sharing it, plus firewall work since active firewalls can block access. The ART-Plan Connect companion application is Windows-only. DICOM integration must be configured, including required tags and output applications. The cloud option removes most hardware constraints. Once live, day-to-day use is browser-based on a 17-inch or larger screen.
Deployment
Integrations
Behind TheraPanacea
Fundraising
Social
Resources
All the official URLs gathered for verification and reference.
Frequently asked questions
What is ART-Plan?
Who is allowed to use it?
How many anatomical structures can it contour?
How long does automatic contouring take?
Can ART-Plan be used to make a diagnosis?
Do the AI-generated contours still need to be checked?
Which treatment planning systems does it work with?
How is it deployed?
How much does it cost?
Where is health data hosted?
Should you pick TheraPanacea?
TheraPanacea is not a general-purpose AI product and should not be judged as one. ART-Plan is a clinical instrument, and its value shows up in throughput and consistency inside a radiotherapy department: 270+ structures contoured in minutes rather than hours, plans built to the same standard whoever is on shift, and adaptive assessments that run overnight instead of waiting for someone to find the time. The maturity signals are genuine — a medical device certified since 2019, 300 clinical sites claimed, segmentation embedded in Brainlab Elements, a partnership with LAP's RadCalc, and a research library of well over a hundred publications and multi-centre evaluations.
The counterweight is how little the buyer can assess alone. There is no price, no published terms of service, no API and no trial: every question ends at a demo request and a contract. Model availability differs by market and the list is never published, automatic planning is validated on three planning system configurations only, and AdaptBox synthetic CT depends on Elekta or Varian CBCT. On-premise deployment means a dedicated server, a properly equipped room and firewall work before anyone contours anything.
On governance the picture is mixed in an interesting way. The footer commitment that no personal health data leaves the European Economic Area is stronger than what most vendors state, and the publisher is French with a named DPO. Yet the only legal document on the site covers website visitors, dates from November 2023, and says nothing about a data processing agreement, subprocessors or retention periods. For a hospital, that means the real diligence happens in the contract. The AI proposes; a qualified human still signs off on every contour and every plan.
- Choosing a selection results in a full page refresh.
- Opens in a new window.